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patients treated with HF, respectively (p=0.154). Grade ≥ 2 late 
genitourinary (GU) toxicity was experienced by 41% and 43% of 
patients treated with SF and HF, respectively (p=0.532). 
From 3 months after RC, only 2% of patients experienced a grade 3 
late GI toxicity in the SF arm versus 1% in the HF arm (p=0.337). Grade 
4 late GI toxicity was reported in 1 patient in the SF arm versus 4 
patients in the HF arm (p=0.373). Late GU grade 3 toxicity was 
reported by 9% and 14% in the SF- and HF arm, respectively (p=123). 
No grade 4 late GU toxicity was reported in the SF arm versus 1 
patient in the HF arm. 
A multivariable analysis evaluating the effect of age, PSA, Gleason-
score, T-stage, use of hormonal therapy, previous TURP, smoking and 
the presence of acute GI/GU toxicity showed that only the presence 
of acute toxicity significantly increased the risk of developing late GI 
toxicity (p=0.000) . For the late GU toxicity, the age >70 (p=0.001), 
the presence of acute GU toxicity (p=0.000) and smoking (p=0.046) 
were significant factors increasing the risk of developing late GU 
toxicity.  
Conclusions: Our initial results on late toxicity, after a median follow-
up of 27 months, show that the hypofractionated treatment is well 
tolerated. No significant differences in late GI and GU toxicity were 
observed compared to the standard fractionation arm. The presence 
of acute GI and GU toxicity were significant prognostic factors for late 
toxicity. Age and smoking were significant prognostic factors for late 
GU toxicity as well.  
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Purpose/Objective: Moderate dose escalation and hypofractionation 
(HYPO) have a possible role in the postprostatectomy (POSTOP) 
setting, both adjuvant (ADV) and salvage (SALV). This analysis focused 
on possible clinical and physico-dosimetric predictors of most severe 
(Grade ≥3) genitourinary toxicity (GU TOX) after POSTOP RT for 
prostate cancer (PCa). 
Materials and Methods: A cohort of 1176 consecutive patients (pts) 
was submitted to POSTOP ADV (n=804) or SALV (n=372) RT between 
1993 and 2010 in a single Institution with conventionally fractionated 
(CF, 1.8 Gy/fraction, fr) non conformal (NC, n=169), 3DCRT (n=657) or 
IMRT (n=103) technique, or moderately HYPO (median 2.50 Gy/fr) 
helical Tomotherapy (n=247). The whole-pelvis (WP) was irradiated in 
345 pts. The median dose to the prostatic bed and WP was 70.2 Gy 
and 50.4 Gy, respectively, in the CF group. For the HYPO group, 3 
cohorts were identified: 116 treated at a median of 65.8 Gy (2.35 Gy x 
28), 76 at 71.4 Gy (2.5-2.6 x 28) and 49 at 58 Gy in 20 Gy. In the HYPO 
group the most common WPRT schedule was 51.8 Gy/28 fr. Total 
doses were also converted in biological equivalent doses (BED) 
following the linear quadratic model (LQ) taking a/b = 3 or 5. We 
focused on Grade ≥3 toxicity, retrospectively graded according to 
CTCAE v 4.0. 
Results: After a median follow-up of 95 months (60 for HYPO), 121 pts 
experienced Grade 3 late TOX (57 urethral or bladder neck strictures 
requiring interventions ± 49 severe urinary incontinence 
onset/worsened after RT ± 25 gross haematuria) and 5 underwent 
cystectomy (Grade 4). Patients were grouped in 3 classes, according 
to the dose/fr received: A=1.8-2.0 Gy, B=2.3-2.4 Gy, C=2.5-2.9 Gy. At 
univariate analysis, the 5-year risk of TOX G≥3 was predicted by 
fractionation (7% vs 15% vs 21% for groups A, B and C, respectively, 
p<0.0001), acute Grade ≥2 TOX (18% vs 8%, p=0.0001) and use of anti-
hypertensives (HYPERT, 12% vs 7%, p=0.04). At multivariate analysis 
(MVA) the only predictive covariate of Grade≥3 TOX in the overall 
population was acute Grade ≥2 TOX (HR 2.49, p=0.0002), while 
fractionation (p=0.06) and HYPERT (p=0.09) were found to be of only 
borderline significance. In the HYPO subgroup, the only significant 
variable at MVA was HYPERT (HR 8.15, p=0.008). Overall, BED was not 
predictive. 
Conclusions: This is the largest data set focusing on the impact of 
different doses and fractionations on severe GU toxicity after POSTOP 
RT for PCa, suggesting the existence of an important 'consequential' 
component for the onset of severe late GU toxicity, and an important 
role of HYPERT. Moreover, the impact of an increased daily dose 
effect (from 1.8-2 to 2.3-2.9 Gy/fr) is completely inconsistent with 
the linear-quadratic model, suggesting that HYPO exacerbates severe 
GU TOX far more than would be expected from BED calculation. This 
effect may suggest an increased incomplete repair effect of the 
urothelium, possibly enhanced by the previous surgery. 
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Based on prospective trials, stereotacticbody radiotherapy (SBRT) has 
become the standard of care for early stage non-small cell lung cancer 
(NSCLC): high accuracy of the whole radiotherapy work-flow allowed 
safe delivery of escalated irradiation doses, which significantly 
improved local tumor control and overall survival compared to 
conventionally fractionated radiotherapy. Local surgical treatment of 
oligo-metastatic lung and / or liver lesions has shown promising long 
term overall survival with cure in a proportion of the patients and 
these results were the rational for exploring the role of SBRT in the 
setting of pulmonary metastases. Until today, several prospective 
trials have investigated safety and efficacy of SBRT in this metastatic 
setting. The majority of the studies limited the number of treated 
pulmonary lesions or lesions anywhere in the body to 3 – 5 and SBRT 
irradiation doses were similar to experiences in SBRT for stage I 
NSCLC, mostly higher than 100Gy BED. However, lesions were rather 
small in the majority of the studies and risk-adapted fractionation 
with larger number of treatment fractions and lower total doses are 
recommended in the situation of multiple large-volume disease. 
Integration of SBRT into systemic chemotherapy is still poorly 
investigated but the majority of the studies did not allow 
simultaneous chemotherapy and recommended a chemotherapy-free 
interval of several weeks prior to and after SBRT. Clinical outcome of 
SBRT for pulmonary metastases is promising with toxicity grade >2 of 
<10%: radiation induced pneumonitis and chest wall pain were the 
most frequently observed toxicities. Local tumor control was 
consistently achieved in 80-90% of the patients. Despite the majority 
of the patients developed progressive systemic disease, long term 
overall survival was observed in a similar proportion of the patients as 
in the surgical series. Despite these promising results, a better 
understanding of how to select patients, which benefit most from this 
local treatment, is warranted. Additionally, the combination of SBRT 
with concurrent chemotherapy and targeted therapy is poorly 
investigated. Finally, endpoints other than overall survival like 
prolonging a chemotherapy-free interval with improved quality-of-live 
are worth to evaluate in future prospective trials. 
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Resection of pulmonary metastases is commonly performed in patients 
whose primary disease is controlled. Lung metastases from a primary 
extra pulmonary malignancy are often a manifestation of widespread 
dissemination; however, some patients have no other evidence of 
disease. The largest number of solitary metastases survivors had 
metastases primarily in the lung and/or liver. With innovations in 
molecular imaging and advances in molecular oncology, the stage is 
set to detect truly solitary metastases early.Then, aggressive 
treatment by surgical excision, stereotactic body radiosurgery, 
targeted chemotherapy, or immunotherapy could eradicate the lesion. 
A broader staging system is recommended to encompass a solitary 
metastasis(M1) and oligometastases (M2) as distinct from multiple 
metastases (M3). Even if nonresectional therapies such as radio 
frequency ablation and stereotactic body radiation therapy are being 
used in centers for patients with oligometastases to the lungs,  
extensive experience with pulmonary metastasectomy in a number of 
different cancers has confirmed that resection can substantially 
prolong survival and cure some patients. Based upon these 
observations, aggressive resection of isolated pulmonary metastases 
has become a widely accepted treatment for appropriately selected 
patients. In addition, technological improvements in radiological 
screening of pulmonary metastases and thoracoscopic resection are 
fundamentally altering the management of these patients and their 
surgery. Despite high resolution computed tomography scan and 
positron emission tomography-computed tomography remain the 
preferred imaging modalities for pulmonary metastases, the 
sensitivity of the technique is 100% for lesions larger than 1 cm, but it 
decreases according to the size of the metastases (<5 mm). Indeed, 
there is a real problem of missing small metastatic lesions in the 
video-assisted thoracic surgery approach; complete manual 
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exploration by axillary-thoracotomy remains the procedure of choice 
for patients undergoing pulmonary metastasectomy, because of 
limitation in preoperative radiological assessment of lung lesions 
smaller than 5 mm. 
We reviewed our series on thoracotomic metastasectomy performed 
for various primary tumors and tried to establish better prognostic 
indicators for its surgical application. 163 patients underwent lung 
metastasectomies from January 2001 to January 2012 in our 
Department. Lung metastases were from colorectal cancer in 75 
patients, renal cells carcinoma in 20, breat in9, gynaecologic tumor in 
17, head and neck cancer in 12, bone and soft tissue sarcoma in 
12,melanoma in 9, hepato and biliary tract in 4 patients. The mean 
disease-free interval (DFI) was 36,9 months. 89 patients had a single-
lung metastasis, 49 oligometastases, 25 multiple metastases.  
The actuarial survival after complete metastasectomy was 83%  at 1 
years, 52%at 5 years and 16% at 10 years.The absence of mediastinal 
lymph node involvement, a limited number of pulmonary metastatic 
lesions, a long disease-free interval, small metastasis, and no 
elevation of tumor markers seem to be prognostic factor in patients 
with pulmonary metastases. The true survival benefits of pulmonary 
metastasectomy remain unclear since there have been no randomized 
trials. However, surgical resection of overt pulmonary metastases can 
render some patients free of disease for long periods. 
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Stereotactic Body Radiotherapy (SBRT) or as it is referred to, 
Stereotactic Ablative Radiotherapy (SABR) has emerged as an 
effective local modality for lung lesions, whether early stage lung 
cancers in medically inoperable patients, or lung metastases from 
other primary tumors. Many series describe the safety and 
effectiveness of lung SBRT – it is well tolerated, convenient for 
patients, non-invasive, and is associated with very mild acute side-
effects, and a low reported rate of significant late effects. The main 
challenges in implementing it for patients with lung metastases lie in 
patient selection, deciding on goals of therapy, and what level of 
evidence is needed to proceed with treatment.  
A rationale approach to offering SBRT for lung metastases is to use the 
same criteria as surgical series, and as documented in the large 
international Lung metastases registry. Patients who are most likely to 
benefit from a radical “curative” approach to their lung metastases 
are those who have no evidence of disease elsewhere, a longer period 
from initial diagnosis to onset of lung metastases, one to max three 
lung metastases and no nodal disease. Critical issues to consider is 
whether this is indeed a metastasis from the previously diagnosed 
extra-thoracic cancer, or possibly a new lung cancer, and what will 
the decision making be once post-SBRT changes on CT scan make the 
assessment of the local control challenging. If the goal of treatment is 
control of the lung lesion with minimal negative quality of life impact, 
then the non-invasive nature of SBRT and low rates of serious side-
effects for peripheral lesions is an attractive consideration.  If 
however the focus is on definitively knowing the status of the lung 
lesions, especially if the patient is fit and a good surgical candidate, 
then the uncertainty of radiological changes post-SBRT is a current 
challenge in managements. Current research will likely shed light on 
this challenge for the future.  For the time being, discussion of 
suitable patients in a multidisciplinary setting, with input from 
treating oncologists and surgical and radiation specialists, and 
education of patients, radiologists and all members of the team to the 
post-SBRT changes will facilitate optimal management of patients, 
while evidence continues to accumulate. 
An interesting question is what evidence should we have in order to 
offer SBRT for patients with lung metastases. Just because we can 
treat lung metastases with SBRT, should we??  An ideal situation would 
be to have high quality data from multiple controlled randomized 
trials, ideally randomizing patients to standard care vs Lung SBRT. An 
immediate question that remains unresolved is what would standard 
care be? Chemotherapy ie systemic therapy alone? No therapy or 
systemic therapy, at the choice of oncologist and patient? Or should 
surgical resection be the control arm?  There are some attempts to 
compare surgical resection to lung SBRT for primary lung cancer, 
although most experts feel that the more pertinent question is 
whether patients (or more likely, which patients) benefit from local 
ablative therapy to their lung metastases. Thus, a randomized study 
of local SBRT therapy vs “management of choice that does not include 
local lung metastases therapy” would be most likely to shed light on 
the benefit of lung SBRT in improving survival, and potentially leading 
to a proportion of patients with lung metastases being cured. Such 
efforts are underway, and will be discussed.  
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Purpose/Objective: Diffusion weighted magnetic resonance imaging 
(DW-MRI) is a functional imaging technique increasingly used for 
tumor and recurrence diagnosis and response prediction and 
monitoring. Due to the high contrast between tumor and surrounding 
tissue, DW-MRI might be a suitable candidate to facilitate GTV 
definition. However, the use of DW-MRI for tumor delineation in head 
and neck RT is hampered by geometric distortions. These distortions 
are caused by the use of echo planar imaging (EPI) in combination 
with an anatomical region with air/tissue transitions. These 
transitions lead to susceptibility differences and thus magnetic field 
(B0) inhomogeneities. 
The EPI distortions can be estimated by characterizing the magnetic 
field inhomogeneities and the effective spectral width per pixel in the 
EPI sequence [Jezzard 1995]. The aim of this study was to quantify 
geometrical distortion of DW-EPI in head and neck tumors. 
Materials and Methods: In this retrospective study, 27 head and neck 
cancer patients scanned between April 2011 and March 2012 were 
analyzed. For these patients, a B0 map was acquired during standard 
RT treatment planning scans. MR imaging was performed at 3.0T 
(Philips Achieva) and the patients were scanned in an RT 
immobilization mask with Flex-M surface coils. 
MR sequences: B0 map: mDixon 3D T1 FFE; 3-point multi acquisition 
Dixon; ΔTE 1 ms; TR/TE 5.7/2.0 ms; acquired voxel size 2.0 x 2.0 x 2.0 
mm3; FOV 250 x 250 x 150 mm3; acquisition time 0m42s. DW-EPI: 
Single shot SE EPI; EPI factor 43; b-values 0, 150, 800 s/mm2; TR/TE 
3699/66 ms; acquired voxel size 3.0 x 3.0 mm2; slice thickness 3.0 
mm; number of slices 40; FOV 250 x 250 x 120 mm3; SENSE factor 2; 
bandwidth/pixel (phase encode) 35 Hz; acquisition time 2m35s. 
GTVs, as delineated by the radiation oncologist, were retrieved and 
transferred onto the acquired B0 maps (fig 1A). The B0 maps were 
converted to pixel shift maps using the bandwidth per pixel from the 
DW-EPI sequence, which was converted to millimeters using the voxel 
size. Statistical analysis was performed on the displacements within 




The displacement occurs only in the phase encoding direction of the 
DW-EPI scan, which was AP. Median displacement is relatively small 
because both positive and negative shifts were found. The median 
minimal and maximal displacements were around 1 cm but the 
extremes showed shifts of more than 2 cm (fig 1B). The distortions 
within the GTV can be estimated from the range in displacements. 
Within the GTV a median range of 2 cm was found with a maximum of 
3.5 cm. If the extremes are ignored, still a median range of shifts of 1 
cm was found (fig 1B). The median fraction of the GTV that showed a 
displacement of 6 millimeters (2 voxels) or more was 0.24 (fig 1C). 
Conclusions: Current DW-EPI images in the head and neck area show 
displacements and distortions up to several centimeters which 
severely restricts its usability for GTV delineation in RT treatment 
planning.  
 
 
 
